This randomised, double-blinded, placebo-controlled phase 3 clinical trial distinguished three groups of patients in the order of increasing efficacy to niraparib: BRCAwt and HR-proficient tumours < BRCAwt and HR-deficient tumours < BRCA1/2 m tumours [14]. This evidence concerns the gene BRCA1 and neoplasm.